2006
Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder
Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. Neurotherapeutics 2006, 3: 69-81. PMID: 16490414, PMCID: PMC3593363, DOI: 10.1016/j.nurx.2005.12.006.Peer-Reviewed Original ResearchConceptsGlutamate modulating agentsObsessive-compulsive disorderTreatment of OCDRecent magnetic resonance spectroscopy (MRS) studyTreatment-resistant obsessive-compulsive disorderModulating agentsGlutamate-modulating drugsThalamo-cortical circuitrySerotonin reuptake inhibitorsElevated glutamate levelsCurrent treatment strategiesMagnetic resonance spectroscopy studyCommon psychiatric disordersNovel pharmacotherapeutic agentsAmyotrophic lateral sclerosisNovel therapeutic interventionsFunctional neuroimaging studiesGlutamate hyperactivityComplete remissionReuptake inhibitorsGlutamatergic activityMetabolic hyperactivitySignificant morbidityCase reportCortico-striato
2005
Clinical treatment of obsessive compulsive disorder.
Pittenger C, Kelmendi B, Bloch M, Krystal JH, Coric V. Clinical treatment of obsessive compulsive disorder. Innov Clin Neurosci 2005, 2: 34-43. PMID: 21120095, PMCID: PMC2993523.Peer-Reviewed Original ResearchObsessive-compulsive disorderSRI-resistant obsessive compulsive disorderMainstay of treatmentSerotonin reuptake inhibitorsEffective treatment modalityUse of clomipramineCurrent treatment strategiesRecent epidemiological studiesCommon psychiatric disordersCompulsive disorderCognitive behavioral therapyInvasive neurosurgical proceduresPartial responseAvailable medicationsPharmacologic treatmentReuptake inhibitorsTreatment armamentariumSignificant morbidityTreatment modalitiesChronic disordersMedication managementTreatment strategiesEpidemiological studiesPsychiatric disordersClinical treatment